How White was paid
$839,476 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Other | Total |
|---|---|---|---|---|---|
| Mark WhiteChief Executive Officer | $300,000 | $280,000 | $241,476 | $18,000 | $839,476 |
| David Owens, M.D.Chief Medical Officer | — | — | $450,077 | $50,600 | $500,677 |
| Carolyn SheltonSenior Vice-President of Quality, Clinical and Regulatory | $300,000 | $40,000 | $51,180 | — | $391,180 |
What changed and why
- $839K$839,476 CEO total compensation in 2025, down from $1,028,470 in 2024.
- $241K$241,476 CEO option awards represented the primary equity component of 2025 compensation.
- $1M$1,000,000 contingent stock options were approved for both White and Owens, pending stockholder approval.
- $100K$100,000 contingent stock options were approved for Shelton, pending stockholder approval.
- $300K$300,000 Shelton salary reflected her first full year after joining in September 2024.
- 2026 compensation consulting support was provided by Willis Towers Watson.
Other Nexalin Technology proxy statements
- 2025 proxy statement
Mark White paid $1M (+51% on the year).
Filed Jun 17, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.